Results 101 to 110 of about 25,056,579 (316)

Arylsulfatase activity in marine polychaetes [PDF]

open access: yes, 1984
Marine polychaetes, collected from the Vellar Estuary exhibited arylsulfatase activity. Lumbriconeries sp. Polydora sp. Monojis sp. and Heteromastus sp. were selected for this study. Of these, Heteromastus sp. showed maximum enzymatic activity and it has
Dhevendaran, K.
core  

Proteome‐Wide Association Study for Finding Druggable Targets in Progression and Onset of Parkinson's Disease

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 2, February 2025.
We identified and validated 25 causal protein targets linked to Parkinson's disease (PD) onset and progression using proteomic and genetic analyses. Using plasma and brain large‐scale pQTL datasets, we conducted proteome‐wide association studies (PWAS) and Mendelian randomization (MR) to assess causality.
Chenhao Gao   +13 more
wiley   +1 more source

Simultaneous determination of minoxidil and minoxidil sulfate by high-performance liquid chromatography with UV-detection and its applications

open access: yesMedicine in Drug Discovery, 2020
Aims: Minoxidil is a hair growth drug for treating androgenetic alopecia. Although minoxidil is generally administered as a topical formulation, this prodrug must be converted to its active form (minoxidil sulfate) by sulfotransferase in hair follicle ...
Mio Ichida   +4 more
doaj  

Chondroitin sulfate degradation and eicosanoid metabolism pathways are impaired in focal segmental glomerulosclerosis: Experimental confirmation of an in silico prediction [PDF]

open access: yesBioImpacts, 2019
Introduction: Focal segmental glomerulosclerosis (FSGS), the most common primary glomerular disease, is a diverse clinical entity that occurs after podocyte injury.
Shiva Kalantari   +5 more
doaj   +1 more source

Restricted-sum-dominant sets [PDF]

open access: yesarXiv, 2017
Let $A$ be a nonempty finite subset of an additive abelian group $G$. Define $A + A := \{a + b : a, b \in A\}$ and $A \dotplus A := \{a + b : a, b \in A~\text{and}~ a \neq b\}$. The set $A$ is called a {\em sum-dominant (SD) set} if $|A + A| > |A - A|$, and it is called a {\em restricted sum-domonant (RSD) set} if $|A \dotplus A| > |A - A|$.
arxiv  

Arylsulfatase K, a Novel Lysosomal Sulfatase [PDF]

open access: yesJournal of Biological Chemistry, 2013
The human sulfatase family has 17 members, 13 of which have been characterized biochemically. These enzymes specifically hydrolyze sulfate esters in glycosaminoglycans, sulfolipids, or steroid sulfates, thereby playing key roles in cellular degradation, cell signaling, and hormone regulation.
Wiegmann, Elena   +5 more
openaire   +2 more sources

Pre‐ADMET studies of 5‐(3′,4′‐dihydroxyphenyl)‐γ‐valerolactone, the bioactive intestinal metabolite of proanthocyanidins

open access: yesArchiv der Pharmazie, Volume 358, Issue 1, January 2025.
The pre‐ADMET properties of 5‐(3′,4′‐dihydroxyphenyl)‐γ‐valerolactone (VL) are evaluated for the first time. VL is rapidly metabolized and absorbed as its sulfate phase II conjugate (valerolactone sulfate). In the human S9 liver fraction, VL is metabolized into glucuronic phase II conjugates.
Larissa Della Vedova   +9 more
wiley   +1 more source

Lead toxicity and genetics in Flint, MI [PDF]

open access: yes, 2018
It has been well established that lead poisoning, as defined by the CDC as blood lead levels (BLLs) at or above 5 μg/dl, can lead to long-term neurotoxic effects in children and requires immediate treatment.
Housman, David E   +2 more
core   +1 more source

Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1989
Metachromatic leukodystrophy is a metabolic disorder caused by the deficiency of arylsulfatase A. Deficiency of this enzyme is also found in apparently healthy individuals, a condition for which the term pseudodeficiency was introduced. The arylsulfatase
V. Gieselmann   +4 more
semanticscholar   +1 more source

Biomarkers for neurodegenerative diseases in regulatory decision‐making by the European Medicines Agency

open access: yesAlzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 11, Issue 1, January-March 2025.
Abstract INTRODUCTION Biomarkers (BMs) are valuable tools to facilitate early diagnosis of (subtypes of) diseases, improve patient selection and stratification, and detect therapeutic effects or safety concerns. This study explores the extent to which BMs are utilized in the development of treatments for neurodegenerative diseases (NDDs), as well as ...
Audrey M. M. Hermans   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy